Dennis Shields was named the first member of Alfa Wassermann Proteomic Technologies’ scientific board last week. Shields is a professor of development and molecular biology, and anatomy and structural biology at the Albert Einstein College of Medicine. Shields received his PhD at the National Institute for Medical Research in London.
Eksigent said this week Kevin Sayer has joined its board. Sayer is a consultant to the drug and biotech industries with expertise in medical devices and finance, Eksigent said in a statement. Sayer has held positions at MiniMed/Medtronic MiniMed, Ernst & Young, and Specialty Labs.